Mary Caffrey

Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.

Clinical pathways in cancer care are beyond the “new” phase, but oncology practices and health systems are still learning all the ways they can bring greater standardization to care, eliminate unnecessary care, improve data collection, and drive value.

Both cancer and its treatments are highly symptomatic, making it difficult at times for clinicians to closely monitor every symptom a patient experiences outside the office walls.

Wells A. Messersmith, MD, reviews key updates to the NCCN guidelines for the treatment of colorectal cancer.